ArticleClinical and experimental medicine2025
miR-7213-5p-mediated suppression of CCL19 in fibroblast cells may attenuate lupus nephritis.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lupus nephritis (LN) is an immune-complex nephritis and one of the most severe organ manifestations of systemic lupus erythematosus. To elucidate the mechanisms underlying LN, we firstly performed comprehensive RNA sequencing and microRNA (miRNA) sequencing analyses on the kidneys of female lupus-prone MRL/lpr mice and female C57BL/6 mice. Our results revealed significant renal impairment in 17-week-old female MRL/lpr mice, as evidenced by elevated 24-hour urinary protein, serum creatinine, and blood urea nitrogen levels, along with severe renal pathology. RNA sequencing identified 100 upregulated and 59 downregulated genes in the kidneys of 17-week-old MRL/lpr mice, which were enriched in immune response, transcriptional regulation, and metabolic reprogramming. MiRNA sequencing further identified 23 upregulated and 9 downregulated miRNAs in MRL/lpr mice. Interaction network analysis revealed that the upregulated miRNAs (miR-3473b and miR-204-3p) were linked to transcriptional regulation and DNA repair, while the downregulated miRNA (miR-7213-5p) was closely associated with immune cell trafficking, immune function regulation, and metabolism. Subsequent validation confirmed the significant downregulation of miR-7213-5p in MRL/lpr kidneys, whereas the levels of its predicted target, CC motif chemokine 19 (CCL19), were significantly elevated in both renal fibroblasts and serum. Mechanistically, miR-7213-5p directly targeted the 3'-untranslated region of CCL19, thereby suppressing both the expression and secretion of CCL19 induced by TNF-α in L929 fibroblasts. These findings highlight the anti-inflammatory role of miR-7213-5p via the regulation of CCL19, suggesting its potential as a therapeutic target for LN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.